Novel C5a receptor antagonists regulate neutrophil functions in vitro and in vivo.
Novel recombinant human C5a receptor antagonists were discovered through modification of the C terminus of C5a. The C5a1-71T1M,C27S,Q71C monomer, (C5aRAM; CGS 27913), was a pure and potent functional antagonist. The importance of a C-terminal cysteine at position 71 to antagonist properties of C5aRAM was confirmed by studying C5a1-71 derivatives with replacements of Q71, C5a derivatives of various lengths (70-74) with C-terminal cysteines, and C5a derivatives of various lengths (71-74) with Q71C replacements. The majority of C5a1-71Q71 derivatives were agonists (C5a-like) in the human neutrophil C5a-induced intracellular calcium mobilization assay. The C5a1-71Q71C derivative was an antagonist. C5a derivatives of lengths 73 and 74 with C-terminal cysteines were agonists, while lengths 70 to 72 were antagonists. C5a derivatives of lengths 72, 73, and 74 with Q71C replacements were agonists, while, again, C5a1-71Q71C was an antagonist. C5aRAM and its adducts, including its dimer, C5aRAD (CGS 32359), were pure antagonists. Additionally, CSaRAM and CSaRAD inhibited binding of 125I-labeled recombinant human C5a to neutrophil membranes (Ki = 79 and 2 pM, respectively), C5a-stimulated neutrophil intracellular calcium mobilization (8 and 13 nM), CD11b integrin up-regulation (10 and 1 nM), superoxide generation (182 and 282 nM), lysozyme release (1 and 2 microM), and chemotaxis (11 and 7 microM). In vivo, intradermal injection of C5aRAM inhibited C5a-induced dermal edema in rabbits. Furthermore, a 5-mg/kg i.v. bolus of C5aRAD significantly inhibited C5a-induced neutropenia in micropigs when challenged with C5a 30 min after C5aRAD administration. C5aRAM and C5aRAD are novel, potent C5a receptor antagonists devoid of agonist or proinflammatory activity with demonstrated efficacy in vitro and in vivo.
Pellas
T C
TC
Novartis Research Institute, Summit, NJ 07901, USA. ted.pellas@pharma.novartis.com
Boyar
W
W
van Oostrum
J
J
Wasvary
J
J
Fryer
L R
LR
Pastor
G
G
Sills
M
M
Braunwalder
A
A
Yarwood
D R
DR
Kramer
R
R
Kimble
E
E
Hadala
J
J
Haston
W
W
Moreira-Ludewig
R
R
Uziel-Fusi
S
S
Peters
P
P
Bill
K
K
Wennogle
L P
LP
D000818:Animals; D015703:Antigens, CD / Q000737:chemistry* / Q000235:genetics; D002469:Cell Separation; D015936:Complement C5a / Q000737:chemistry / Q000235:genetics / Q000494:pharmacology*; D019281:Dimerization; D004487:Edema / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D007271:Injections, Intradermal; D007275:Injections, Intravenous; D009503:Neutropenia / Q000276:immunology / Q000517:prevention & control; D009504:Neutrophils / Q000276:immunology* / Q000378:metabolism; D010446:Peptide Fragments / Q000138:chemical synthesis / Q000494:pharmacology; D011817:Rabbits; D044087:Receptor, Anaphylatoxin C5a; D011951:Receptors, Complement / Q000037:antagonists & inhibitors* / Q000737:chemistry* / Q000235:genetics; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D013552:Swine; D013556:Swine, Miniature
D015703:Antigens, CD; C112335:C5aRAD; C112334:CGS 27913; D010446:Peptide Fragments; D044087:Receptor, Anaphylatoxin C5a; D011951:Receptors, Complement; D011994:Recombinant Proteins; D015936:Complement C5a